Keywords: access, reap, benefits, licensing, deals, usa-based, pharmaceuticals
Access to reap the benefits of licensing deals
Article | 20 January 2003
USA-based Access Pharmaceuticals says that its agreements relating tothe canker sore treatment amlexanox could generate some $6.7 million in licensing fees, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
